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Edited by Gunnar von Heijne and Anders LiljasAbstract Imaging of biochemical processes in living cells and
organisms is essential for understanding how genes and gene
products work together in space and time and in health and dis-
ease. Such imaging depends crucially on indicator molecules de-
signed to maximize sensitivity and speciﬁcity. These molecules
can be entirely synthetic, entirely genetically encoded macromol-
ecules, or hybrid combinations, each approach having its own
pros and cons. Recent examples from the authors laboratory in-
clude peptides whose uptake into cells is triggered by proteases
typical of tumors, monomeric red ﬂuorescent proteins and biar-
senical–tetracysteine systems for determining the age and elec-
tron-microscopic location of proteins.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Tetracysteine1. Introduction
The 20th century witnessed explosive progress in macromo-
lecular biochemistry and genetics, which started with the redis-
covery of Mendelian genetics and the recognition of
biopolymers and culminated in the sequencing of complete
genomes. However, genome sequences alone lack spatial and
temporal information and are therefore as dynamic and infor-
mative as census lists or telephone directories. The challenge
for the 21st century is to ﬁgure out how these casts of molec-
ular characters work together to make living cells and organ-
isms and how such understanding can be harnessed to
improve health and wellbeing. I believe this quest will depend
heavily on molecular imaging, which shows when and whereAbbreviations: GFP, green ﬂuorescent protein; FRET, ﬂuorescence
resonance energy transfer; CFP, cyan ﬂuorescent protein; YFP, yellow
ﬂuorescent protein; mRFP1, monomeric red ﬂuorescent protein, 1st
version; Kd, dissociation constant; ROS, reactive oxygen species; CaM,
calmodulin; ER, endoplasmic reticulum; cAMP, cyclic adenosine 3 0,50-
monophosphate; PKA, protein kinase A or cAMP-dependent protein
kinase; AKAR2, A-kinase activity reporter, 2nd version; FlAsH, ﬂu-
orescein-based arsenical hairpin binder; ReAsH, resoruﬁn-based ars-
enical hairpin binder; PF, cerebellar parallel ﬁber; PC, Purkinje cell;
LTP, long-term potentiation
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doi:10.1016/j.febslet.2004.11.025genetically or biochemically deﬁned molecules, signals or pro-
cesses appear, interact and disappear, in time and space.
Therefore, molecular imaging synergistically draws upon phys-
ics, chemistry, anatomy, physiology, biochemistry and genet-
ics.
Our ﬁrst signiﬁcant contribution to molecular imaging was a
series of organic chemical buﬀers and indicators (reviewed in
[1,2]) for intracellular calcium (Ca2+), which is a crucially
important messenger inside cells. We also synthesized novel
molecules to measure other intracellular signals such as so-
dium [3] and proton concentrations [4], gene expression [5]
and membrane potential [6–8].
In the mid-1990s, we began to put most of our eﬀort into
developing genetically encoded macromolecular indicators,
which are usually administered not as ready-made proteins
but as genes, which tell the cell or organism to make the indi-
cators to our speciﬁcations. The key building blocks for such
genetically encoded indicators are mutants of the green ﬂuores-
cent protein (GFP) [9] from the jellyﬁsh Aequorea victoria.
GFP was discovered as a protein by Shimomura [10], the gene
was cloned by Prasher [11], and Chalﬁes and Tsujis labs
[12,13] ﬁrst reported heterologous expression. GFP and its rel-
atives have become tremendously useful in many areas of
molecular and cell biology because they provided the ﬁrst
means by which a simple gene could give rise to bright visible
ﬂuorescence. Whenever scientists want to make a cellular pro-
tein ﬂuorescent, their ﬁrst thought nowadays is to fuse the gene
for their favorite protein to the gene for a ﬂuorescent protein
(FP), then put this composite gene back into the cell or organ-
ism of interest. If all goes well, the hybrid generates a chimeric
protein in which the host component goes about its normal
business, while the attached FP ﬂuoresces and reports the pres-
ence and position of the pair [9] (see Fig. 1).
Dr. Roger Heim in my lab started working in 1992 on the
GFP gene provided by Prasher [11]. We very much wanted
to create mutants with brighter ﬂuorescence, because the origi-
nal GFP was dim, ﬁckle and spectrally impure. We also
wanted diﬀerent colors to enable ﬂuorescence resonance en-
ergy transfer (FRET), which inherently requires a pair of col-
ors. Heim developed the ﬁrst mutants in which the spectrum of
GFP was simpliﬁed and enhanced [14]; one of these mutations
(S65T), right next to the chromophore, is at the heart of the
optimized GFPs now routinely used around the world. Heim
also created blue and cyan-emitting mutants, BFPs and cyan
ﬂuorescent protein (CFPs), respectively [15,16]. Later we
helped Prof. Jim Remingtons group to solve the X-ray crystal-
lographic structure of GFP, which immediately suggested ablished by Elsevier B.V. All rights reserved.
Fig. 1. Engineered ﬂuorescent proteins cover the full visible spectrum of emissions. Protein samples were puriﬁed from E. coli expression systems,
excited at wavelengths up to 560 nm and photographed by their ﬂuorescence. The excitation and emission maxima are listed above the sample tubes
and the names below the tubes.
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Andrew Cubitt made the appropriate mutants, whose yellow-
ish appearance led to the name of yellow ﬂuorescent protein
(YFPs). Currently, the best pair for FRET consists of the cyan
and the yellow mutants, CFP and YFP, respectively.2. Recent progress (1999–2004) in understanding and improving
ﬂuorescent proteins
For most applications of YFPs, it is important to minimize
their sensitivity to pH, [Cl] and photo bleaching. We found a
mutant of YFP (Q69M) with greater resistance to these factors
and solved the crystal structure, which showed that the Met
ﬁlled a cavity in previous YFPs [18]. We destroyed the weak
dimerization of CFP/YFP to probe loose association of mem-
brane-anchored versions in or out of lipid rafts [19].
The cloning of the ﬁrst red ﬂuorescent protein, DsRed [20],
revealed nothing about its post-translational biochemistry. We
showed that DsRed is an obligate tetramer, which ﬁrst be-
comes green-ﬂuorescent before ﬁnally maturing slowly and
incompletely to red [21]. Such tetramerization explained why
most attempts to fuse DsRed to other proteins produce mistar-
geting or toxicity. Mass spectrometry told us the covalent
structure of the chromophore, formed from the GFP chromo-
phore by an unprecedented dehydrogenation of a Ca–N bond
[22]. X-ray crystallographers [23,24] conﬁrmed the structure by
observing the subtle change of that Ca from tetrahedral to tri-
gonal. The intimacy of the intersubunit contacts led to predic-
tions that the tetramer would be impossible to break [25], but
we succeeded [26]. The resulting monomeric red ﬂuorescent
protein, ‘‘mRFP1’’ has become very popular for many in vivo
applications [27–30].Although others have discovered coral ﬂuorescent proteins
of varied colors, all have been wild-type tetramers. Also
improvements in mRFP1 brightness and photostability would
be desirable. Therefore, Nathan Shaner has evolved mRFP1
into brighter monomers ranging in emission between 534 and
638 nm. For example, ‘‘mCherry’’ matures more quickly and
completely than mRFP1, giving higher extinction coeﬃcient
and brightness, yet bleaches about 10-fold more slowly [77].
Lei Wang developed an alternative method for evolving no-
vel protein properties directly in mammalian cells by harness-
ing somatic hypermutation, the process by which B
lymphocytes constitutively mutate genes for immunoglobulin
or other highly expressed proteins up to 106 faster than normal
[31]. mRFP1 was stably transfected into the B-cell line Ramos
with expression controllable by doxycycline. Cells with pro-
gressively red-shifted ﬂuorescence emissions were selected by
ﬂuorescence-activated cell sorting. After over 23 generations
of selection, the emission peak gradually shifted to 648 nm,
36 nm longer than parental mRFP1 and beyond any found
by semi-rational in vitro mutagenesis [78].3. Fluorescent-protein-based indicators
Redox. James Remingtons lab invented redox indicators
consisting of GFP mutants with cysteine pairs, whose revers-
ible oxidation to a disulﬁde profoundly shifts the excitation
spectrum to shorter wavelengths, enabling ratiometric mea-
surement [32]. Colette Dooley [33] characterized and applied
these indicators in live cells, targeted them to cytosol, plasma
membrane and nucleus and increased their oxidation sensitiv-
ity by placing positive charges next to the cysteines to lower the
pKa of the latter. The redox indicators become substantially
R.Y. Tsien / FEBS Letters 579 (2005) 927–932 929oxidized in response to exogenous oxidants or oxidative bursts
in HL60 cells. Despite considerable eﬀort, we have not found
responses to growth factor stimulation, suggesting that if reac-
tive oxygen species (ROS) are as important in mitogenic sig-
naling as widely believed, such ROS must be very transient
or localized.
Ca2+. Geoﬀ Baird showed [18,34] that GFPs could be circu-
larly permuted and that conformationally sensitive receptor
domains could be inserted within the GFP to generate indica-
tors (e.g., camgaroos’’) with large-amplitude responses to
binding of ligands such as Ca2+. Camgaroos have provided
useful signals in Drosophila [35] and inspired higher-aﬃnity
Ca2+ indicators such as ‘‘G-CaMP’’ and ‘‘pericams’’ from
other groups [36,37], which have become some of the most
promising genetically encoded indicators of neuronal network
activity [38,39].
Our FRET-based sensors of Ca2+, the ‘‘cameleons’’ [40–42],
remain advantageous for their emission of ratiometric response
and avoidance of the intrinsic pH-sensitivity of the camgaroo/
G-CaMP/pericam family. Cameleons have revealed important
biology in plants [43,44] and nematodes [45–47]. Transgenic
mice expressing cameleons were the testbed for a new combina-
tion of 2-photon imaging and laser ablation for serial recon-
struction of tissue volumes [48] and have shown some
promise for neuronal activity monitoring [39]. Nevertheless,
cameleons in transgenic mice and next to Ca2+ channels are
much less Ca2+-responsive than cameleons transiently ex-
pressed in the cytosol. Our previous cameleons do suﬀer from
CaM interference and we hypothesize that endogenous calmod-
ulin (CaM) is upregulated upon long-term cameleon expression
and is already concentrated next to channel mouths [49]. There-
fore, Amy Palmer re-engineered the CaM-M13 interface by
reversing salt bridges or computationally designing comple-
mentary bumps and holes (the latter in collaboration with the
lab of David Baker, HHMI, U. Washington). The new came-
leons have eﬀective dissociation constant (Kds) for Ca
2+ of
600 nM or 60 lM, with much better resistance to native CaM
(up to 0.8 mM) and faster response kinetics than the original
cameleons. The low-aﬃnity indicator also greatly improves
imaging of lumenal Ca2+ in the endoplasmic reticulum (ER).
For the ﬁrst time, we can measure (a) [Ca2+]ER oscillations in
antiphase to cytosolic Ca2+; (b) the quantitative relationship
between [Ca2+]ER and eﬄux from the ER when SERCA-medi-
ated inﬂux is blocked; (c) increased permeability and decreased
[Ca2+]ER when the antiapoptotic gene Bcl-2 is expressed; (d)
reversal of the Bcl-2-mediated leak by natural products from
green tea, possibly explaining why such compounds can restore
apoptosis of Bcl-2-expressing malignant cells [79].
The higher aﬃnity cameleon has a Kd of 600 nM, ideally
positioned to detect modest elevations of Ca2+ over basal lev-
els. Preliminary tests show that the improved cameleon works
under circumstances where the original cameleon gave non-
sensical results, but the real challenge will be in transgenic
mice, which are currently being bred.
Kinase activities. We created indicators for kinases such as
epidermal growth factor receptor, Src, Abl [50], protein kinase
A (PKA) [51] and protein kinase C [52]. Generically, these
indicators fuse CFP, a phosphoaminoacid-binding domain, a
substrate peptide and YFP. Peter Wang, a postdoc bridging
Shu Chiens and my lab, has improved the speciﬁcity of the
Src reporter by replacing its original substrate peptide by
one derived from p130cas. He is seeing interesting localizedactivation of Src in endothelial cells touching adherent beads
pulled by laser tweezers.
Jin Zhangs [51] original PKA reporter AKAR1 had given
mostly irreversible responses in cells. Replacing the 14-3-3 do-
main, which binds phosphoserine very tightly, with an FHA1
domain, which binds phosphothreonine less tightly, generated
A-kinase activity reporter, 2nd version (AKAR2), which is
quite reversible. Our foremost application of AKAR2 is to ex-
plore insulin antagonism of PKA in adipocytes, which has po-
tential signiﬁcance for obesity. Jerrold Olefskys lab, our
collaborators, had shown [53] that chronic insulin exposure en-
hances cAMP generation by b2-adrenergic stimulation but had
no eﬀect on cAMP elicited by forskolin, a direct agonist for
adenylate cyclase. We now ﬁnd that chronic insulin pretreat-
ment of 3T3-L1 adipocytes delays PKA activation by b-adren-
ergic stimulation despite the enhanced cAMP production. The
divergence between total cAMP vs. PKA activity is seen only
with b-adrenergic stimulation, not with other ways of raising
cAMP, e.g., forskolin or photolysis of caged cAMP. Endoge-
nous CREB phosphorylation agrees qualitatively with the
AKAR2 responses. Ht31, a dominant-negative peptide known
to disrupt PKA anchoring [54], largely mimics insulins prefer-
ential inhibition of b-adrenergic activation of PKA. We
hypothesize that chronic insulin pretreatment disrupts prefer-
ential coupling of b-adrenergic receptors to localized cAMP
and PKA, which would exemplify a novel mechanism for het-
erologous crosstalk between signal transduction pathways.
Glutamate. Optical indicators of glutamate would be useful
to image glutamate without concerns of up/downregulation
or desensitization of endogenous receptors and to map the spa-
tial spread of glutamate. Andrew Hires has created glutamate-
sensitive ﬂuorescent reporters (GluSnFRs) by fusing CFP, GltI
(a periplasmic glutamate-binding protein from E. coli) and
YFP. Semirational mutations vary the Kd for glutamate from
0.15 to 700 lM. When GluSnFR is expressed on cultured hip-
pocampal neurons but not localized at synapses, he and Yon-
gling Zhu in Charles Stevens lab can image electrically evoked
[Glu] transients, which vary with extracellular Ca2+ and Mg2+
as expected for synaptic release and are ampliﬁed 3-fold by a
glutamate reuptake inhibitor. Averaging across the dendritic
surface shows responses to single action potentials, peaking
within 50 ms and returning to baseline within 200 ms. Averag-
ing across multiple stimuli shows some dendritic hotspots that
respond most strongly to the ﬁrst action potential of a short
spike train, while other hotspots prefer the second, consistent
with heterogeneity of paired-pulse facilitation vs. depression
across synaptic sites.4. Biarsenical–tetracysteine labeling system
Although FPs have enormously advanced molecular and cell
biology, they do have important limitations. They are at least
220 amino acids in size, so that they are often bigger than the
host protein to which they are fused. Their only basic function
is ﬂuorescence, whereas artiﬁcial small molecule probes
encompass a much wider range of useful properties. Ideally,
one would like to combine the genetic targetability of ﬂuores-
cent proteins with the versatility and small size of organically
synthesized dyes. A solution to this challenge is to tag the pro-
tein of interest with a very small peptide domain, whose essen-
tial core is just two cysteines, two spacer amino acids



































Fig. 2. Schematic mechanism for peptides whose uptake is dependent
on protease activity. The red segment represents a row of D-
glutamates, the green segment a cleavable linker, the blue segment a
row of D-arginines and the yellow circle an imaging or therapeutic
cargo.
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57]. This motif can be labeled in living intact cells with mem-
brane-permeant dyes that carry two arsenic atoms along one
edge. Each pair of cysteines binds to one of the arsenics, prob-
ably causing the peptide to bend into a hairpin conformation.
We have synthesized a variety of biarsenical dyes that can ﬁt
into the same peptide domain, but the most useful are a
green-emitting ﬂuorescein-based dye called FlAsH (for ﬂuores-
cein-based arsenical hairpin binder) and a red-emitting resoru-
ﬁn-based analog called ReAsH (for resoruﬁn-based arsenical
hairpin binder). FlAsH and ReAsH are both able to cross
mammalian cell membranes. They are delivered pre-bound to
an antidote, 1,2-ethanedithiol, that minimizes toxicity by pro-
tecting endogenous thiols from the arsenics. The antidote also
keeps the dyes relatively non-ﬂuorescent until they ﬁnd their
target tetracysteine domains. A single tetracysteine site can
bind either FlAsH or ReAsH with picomolar aﬃnity, but
not both at the same time. Once bound, the dyes remain stably
attached for days under normal conditions.
Pulse-chase labeling and singlet-oxygen-(1O2)-mediated elec-
tron microscopic photoconversion of tetracysteine-tagged
connexin-43 revealed the life cycle of this major constituent
of gap junctions [58]. Analogous pulse-chase labeling of neuro-
nal AMPA receptors (GluR1 and GluR2) gave many insights
into their regulation and traﬃcking, including direct evidence
that they can be synthesized de novo in microsurgically iso-
lated dendrites [59]. Protein folding and aggregation have been
monitored in real time within fairly intact bacteria [60]. Intense
illumination of FlAsH or ReAsH can inactivate the tetracys-
teine-tagged protein, providing a genetically targeted strategy
for sudden (and potentially localized) functional knockout of
speciﬁc proteins [61–64].
Improved tetracysteine sequences. Brent Martin has com-
pleted a FACS-based genetic screen to identify the optimal
X1–6 surrounding the Pro-Gly tetracysteine motif, i.e.,
X1X2X3CCPGCCX4X5X6, fused to the N-terminus of GFP.
A mammalian cell-based library of >107 clones was screened
based on ReAsH binding and ﬂuorescence in the face of
increasing levels of dithiol antidote. After 16 rounds of selec-
tion by FACS, several superior sequences emerged, including
our present favorite, FLNCCPGCCMEP. The new motif ex-
presses more eﬃciently, exhibits 3 orders of magnitude in-
crease in aﬃnity as judged by resistance to dithiols and
demonstrates a ReAsH quantum eﬃciency of 0.47, about 2-
fold higher than earlier peptides. The new tetracysteine peptide
displays >25-fold improvement in contrast over previously
published peptides in living cells, enhancing the contrast to lev-
els approaching that of GFP. These improvements have been
transferable to either terminus of GFP as well as to direct fu-
sions to b-actin and a-tubulin. The new tetracysteine motif sig-
niﬁcantly reduces background and enhances sensitivity, which
should enable imaging or photoinactivation of a much broader
spectrum of cellular proteins.
New applications. Oded Tour and Stephen Adams have
bound a biarsenical, low Ca2+-aﬃnity derivative of Calcium
Green to tetracysteine-tagged voltage-gated Ca2+ channels,
as an alternative to cameleon fusions, to sample the nanome-
ter-sized local [Ca2+] domains at the channel mouths. Total
internal reﬂection microscopy excludes background signals
including channels that are not yet inserted into the plasma
membrane. Preliminary indications are that the local Ca2+
concentrations are not as high as widely supposed from mod-eling studies and that channels clustered in patchy hot spots
rather than randomly distributed.5. Aptamer labeling
Jeremy Babendure discovered that two series of RNA apta-
mers (38–54 nucleotides in length) developed for other purposes
[65,66] could each bind a diﬀerent series of poorly ﬂuorescent
dyes with 0.12–86 lM Kds while enhancing the ﬂuorescence
by >2000 and 100-fold, respectively [67]. Such aptamers
would constitute compact fusion tags for intracellular RNAs
except that cells unfortunately contain other constituents that
enhance the ﬂuorescence of these triphenylmethane dyes. Ste-
phen Adams made related dyes that show extremely little ﬂuo-
rescence in cells, but those dyes would require new aptamers.6. Synaptic plasticity
Varda Lev-Ram discovered a new form of long-term poten-
tiation (LTP) at the parallel ﬁber (PF) to Purkinje cell (PC)
synapse, elicited by 1 Hz PF stimulation without a rise in PC
[Ca2+]cyto. Unlike the previously known cAMP-mediated pre-
synaptic form of LTP [68], the new LTP is postsynaptic, nitric
oxide-mediated and a mutually reciprocal resetting mechanism
for classic coincidence-dependent long-term depression [69,70].7. Tumor imaging
For clinical applications, one would prefer not to have to
introduce genes or be limited to optical detection. Arginine-
rich sequences are known [71–76] to mediate uptake of a wide
variety of contrast agents into cells and tissues in vivo. Tao
Jiang found that such uptake can be prevented by appending
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cleavage of the linker (Fig. 2). This new mechanism oﬀers
the exciting possibility that radioactive, magnetic and infrared
contrast agents and therapeutic drugs may be concentrated in
diseased tissues expressing particular extracellular proteases, as
typical for invasive tumors. Emilia Olson has obtained prom-
ising image contrast from human tumors xenografted into
mice, as well as squamous ccll carcinomas freshly resected
from patients by Dr. Quyen Nguyen [80].8. Conclusions
Here are some general conclusions that I would draw from 30
years of trying to engineeringmolecules to report cellular events:
 Deliberate design and synthesis of molecules (both small
and macro) can have a signiﬁcant impact on cell biology
and drug discovery.
 Many aspects of chemistry, cell biology and some physics/
instrumentation must be closely integrated.
 Small teams of 1–2 postdocs/students in an academic lab of
3–15 can make basic progress in 0.5–5 years (huge teams
not required).
 Translation to medical/pharmacological treatments does re-
quire industrial participation.
 Most major biochemical signals can now or will soon be
visualized in live cells.
 Cells are highly individualistic; spatial organization (micro-
scopic and submicroscopic) and temporal patterning are
all-important.
The type of research that we have done is sometimes dis-
missed as technology development, inferior to pure biology.
However, in many cases a relatively modest investment in
developing powerful and general methods can solve a wide
range of longstanding biological questions or enable transla-
tion of biological knowledge into practical clinical advances.
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